Active Ingredient History
Aliskiren – the only direct renin inhibitor which is clinically used as an antihypertensive drug. Aliskiren is the first of a new class of antihypertensive agents. Aliskiren is a new renin inhibitor of a novel structural class that has recently been shown to be efficacious in hypertensive patients after once-daily oral dosing. In short-term studies, it was effective in lowering blood pressure either alone or in combination with valsartan and hydrochlorothiazide, and had a low incidence of serious adverse effects. It was approved by the Food and Drug Administration in 2007 for the use as a monotherapy or in combination with other antihypertensives. Aliskiren is marketed under the trade name Tekturna. Aliskiren effectively reduces functional plasma renin activity by binding to renin with high affinity, preventing it from converting angiotensinogen to angiotensin I. The inhibition of renin by aliskiren is associated with a reduction in circulating levels of angiotensin I and II, with a resultant increase in plasma renin concentration and inhibit activation of mitogen-activated protein kinases ERK1 (p44) and ERK2 (p42). NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Acute Coronary Syndrome (Phase 2)
Albuminuria (Phase 4)
Atherosclerosis (Phase 2/Phase 3)
Atrial Fibrillation (Phase 3)
Blood Pressure (Phase 4)
Cardiovascular Diseases (Phase 3)
Complement Pathway, Classical (Phase 2)
Coronary Artery Disease (Phase 4)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Diabetic Nephropathies (Phase 4)
Dialysis (Phase 4)
Edema (Phase 2)
Endothelial Cells (Phase 3)
Essential Hypertension (Phase 4)
Glomerulonephritis (Phase 2)
Glomerulonephritis, IGA (Phase 4)
Glomerulonephritis, Membranous (Phase 4)
Glomerulosclerosis, Focal Segmental (Phase 4)
Healthy Volunteers (Phase 1)
Heart Failure (Phase 4)
Heart Transplantation (Phase 4)
Hypertension ()
Hypertrophy, Left Ventricular (Phase 4)
Insulin Resistance (Phase 2)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 4)
Macular Edema (Phase 2)
Marfan Syndrome (Phase 3)
Membranes (Phase 4)
Metabolic Syndrome (Phase 4)
Muscles (Phase 4)
Myocardial Infarction (Phase 3)
Myocardial Ischemia (Phase 2)
Obesity (Phase 4)
Obesity, Abdominal (Phase 4)
Overweight (Phase 3)
Prehypertension (Phase 4)
Proteinuria (Phase 4)
Renal Insufficiency (Phase 2)
Renal Insufficiency, Chronic (Phase 4)
Sclerosis (Phase 4)
Vitamin D Deficiency (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue